Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3680 - The prevalence of CD146 expression in breast cancer subtypes and its relation to outcome


11 Sep 2017


Poster display session


Translational Research;  Breast Cancer


Ingeborg de Kruijff


Annals of Oncology (2017) 28 (suppl_5): v43-v67. 10.1093/annonc/mdx362


I.E. de Kruijff1, A.M. Timmermans1, M.A. den Bakker2, A.M.A.C. Trapman1, R. Foekens1, E. Oomen-De Hoop1, M. Smid1, A. Tjon A Fat - Hollestelle1, C.H.M. van Deurzen2, M.E. Meijer - van Gelder1, J.A. Foekens1, J.W.M. Martens1, S. Sleijfer1

Author affiliations

  • 1 Department Of Medical Oncology And Cancer Genomics Netherlands, Erasmus MC Cancer Institute, 3075 EA - Rotterdam/NL
  • 2 Department Of Pathology, Erasmus MC Cancer Institute, 3075 EA - Rotterdam/NL


Abstract 3680


CD146 has several putative (patho)physiological roles in breast cancer. The most prominent is its involvement in the induction of epithelial-to-mesenchymal transition, which might have an effect on cancer phenotype and aggressiveness. Here, we investigated the prevalence of CD146 expression and its prognostic role in breast cancer subtypes.


In total, 1,025 breast cancer patients were available for this retrospective study. From all patients, formalin-fixed paraffin-embedded primary breast cancer tissue was collected and embedded in tissue microarrays, which were stained for CD146. CD146 expression was defined as > 1% of the tumor cells showing CD146 membrane staining. Clinical data were available from all patients (median follow up 118 months, range 4-120). For subtype analysis the Pearson chi-square test was used and the Cox proportional hazards model for survival analyses. Only patients who were lymph node negative and did not receive (neo)adjuvant systemic treatment were included in the survival analyses (n = 551).


113 (11%) out of 1,025 tumors showed CD146 expression. Of these, 43% of the tumors had > 50% of the tumor cells showing CD146 membrane staining. From the molecular subtypes, CD146 positive tumors are often of the triple negative subtype (76 out of 119 (64%), p 


CD146 protein expression is present in 11% of the primary breast cancer tumors and is most prevalent in the triple negative and medullary subtypes. CD146 is a prognostic factor for MFS and OS in breast cancer patients, but it is not independent of the traditional prognostic factors. Its potential impact on outcome to systemic treatment such as endocrine therapy, remains to be established.

Clinical trial identification

Legal entity responsible for the study

Erasmus University Medical Center




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.